Sign up
Pharma Capital

Citi thinks generic competition to Indivior’s Suboxone drug later this year is “unlikely”

With various patent claims and appeals hanging over the opioid treatment, Citi thinks it is “unlikely” that any generic drugmaker will release a copycat version before the end of the year
suboxone drug
Indivior hopes that an injectable version of the drug will offset any revenue losses from its older product

Analysts at Citigroup don’t expect generic drugmakers to release a copycat version of Indivior PLC’s (LON:INDV) top-selling opioid treatment this year.

The blue-chip bank is “conservatively” modelling for generic competition to Suboxone at the end of this year, although it thinks rivals are “unlikely” to launch a copycat with patent claims and counter-claims hanging over the drug.

READ: Indivior tumbles after patent setback 

Earlier this year, regulators ruled that US drugmaker Alvogen was clear to launch its version as it didn’t infringe on any of the three patents put forward by Indivior.

FTSE 250-listed Indivior, keen to protect its star asset, appealed the ruling, claiming that Alvogen’s under-the-tongue film infringed some of its other patents as well.

Indivior has already reached a deal with Par Pharmaceutical which means its generic rival won’t hit the market until 2023.

If the company is able to achieve a similar result with Alvogen and other generic drugmakers such as Teva, Actavis and Dr Reddy’s – it is pursuing lawsuits against all of them as well – that would add 109p to Indivior’s share price, according to Citi analyst Nick Nieland.

READ: Indivior settles with Par Pharma

With pressure on Suboxone, Indivior launched an injectable opioid treatment called Sublocade earlier this year which it hopes will offset any lost revenues from its older product.

“The success of Sublocade roll out is key to the company’s future,” wrote Nieland in a note to clients.

“[The] valuation is highly sensitive to peak sales assumption for this product (upwards of US$1bn), launched in February 2018.”

For now though, the analyst has downgraded the stock to ‘neutral’ with a price target of 500p, stating that the recent strong run in the shares, coupled with the fact that initial sales of Sublocade won’t be known for a little while, makes Indivior unattractive at this moment in time.

Indivior shares were broadly flat at 457.3p in late-morning trading on Tuesday.



Register here to be notified of future INDV Company articles
View full INDV profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.